DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: AEB071

First Posted Date: 2007-12-13

Last Posted Date: 2020-12-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00572585

Locations: 🇵🇱
Novartis Investigative Site, Poznan, Poland

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: placebo
Drug: indacaterol
Drug: indacaterol/glycopyrrolate

First Posted Date: 2007-12-11

Last Posted Date: 2018-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT00570778

Locations: 🇳🇱
Novartis Investigator Site, Veldhoven, Netherlands
🇳🇱
Novartis Investigator site, Eindhoven, Netherlands
🇳🇱
Novartis investigator site, Heerlen, Netherlands

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: LBH589

First Posted Date: 2007-12-10

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00570284

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Panobinostat
Drug: Trastuzumab

First Posted Date: 2007-12-05

Last Posted Date: 2016-05-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT00567879

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
VA Maryland Health Care Dept.of GreenbaumCancerCent(3), Baltimore, Maryland, United States

and more 5 locations

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

Phase 4

Completed

Conditions: Graft Vasculopathy

Interventions: Drug: Fluvastatin

First Posted Date: 2007-11-30

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT00565474

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Spain

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Phase 4

Completed

Conditions: Myelodysplastic Syndromes
Beta-Thalassemia

Interventions: Drug: deferasirox

First Posted Date: 2007-11-29

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 309

Registration Number: NCT00564941

Locations: 🇭🇺
Novartis Investigative Site, Szeged, Hungary

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Dex-methylphenidate hydrochloride extended-release (Focalin XR)
Drug: Placebo

First Posted Date: 2007-11-29

Last Posted Date: 2012-04-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT00564954

Locations: 🇺🇸
Novartis Investigative Site, Lubbock, Texas, United States

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Phase 1

Completed

Conditions: Advanced or Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: everolimus

First Posted Date: 2007-11-20

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT00560963

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Phase 1

Completed

Conditions: β-thalassemia
Transfusional Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2007-11-20

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT00560820

Locations: 🇮🇹
Novartis Investigative Site, Orbassano, Italy

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

Phase 2

Terminated

Conditions: Kidney Transplantation

Interventions: Drug: mycophenolic plus tacrolimus
Drug: AEB071

First Posted Date: 2007-11-09

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT00555789

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy